University of Toronto

Genentech, Inc.

Albert Einstein College of Medicine

US Government As Represented by the Secretary of the Army

University of Texas System

Other

Mcmaster University

University of Saskatchewan

The University of Western Ontario

Sinai Health System

Reflexion Pharmaceuticals, Inc.

Modmab Therapeutics Corporation

Saksin Lifesciences Pvt. Ltd.

Sidhu, Sachdev

Angers, Stephane

Sachdev Singh Sidhu

Frederic Fellouse

Germaine G Fuh

Christian Wiesmann

Wei-Ching Liang

Hans-Peter Gerber

Jonathan R Lai

Jason Moffat

Kartik Chandran

Guohua Pan

Julia Frei

Orson W Moe

John M Dye

Makoto Kuro-o

Gang Chen

Samantha Zak

Amandeep Gakhal

Sarah L Barker

Evripidis Gavathiotis

Andrew Emili

Kyrylo Zagorovsky

Stephane Angers

Warren C W Chan

Jayne F Koellhoffer

Megan McLaughlin

Jonathan Buchanan Olsen

Henry Bernard Lowman

Yingnan Zhang

Wei Zhang

Michelle Schaffer

Kurt Deshayes

Mike Costa

Maruti Uppalapati

Helena Persson

Nish Patel

Saravanan Sundararajan

Wei Ye

Jelena Tomic

Megan Elizabeth Mclaughlin

Melanie Robitaille

Linda Beatty

Andreas Ernst

Johanne Pastor

James A Wells

Menno Van Lookeren Campagne

Stephen B H Kent

Christopher John Bond

Bing Li

Gregory A Weiss

Clarence Ronald Geyer

Shun-Cheng Li

Dana Ault-Riche

Frank Sicheri

Daniel Durocher

Haiming Huang

Shane Miersch

Jayne F Koelhoffer

Zachary Steinhart

Sara C Birtalan

Jarrett Adams

Xiaowei Wang

Cn Ramchand

Rashida Williams

Xiaoyu Zhang

Marella Canny

Sheila K Singh

Ravikant Harit

Parvez Vora

Reena Arora

Chitra Venugopal

Aju Antony

Maryna Gorelik

Santhi Vinodh

Tomonori Kaneko

Xuan Cao

Aaron Kerman

Makoto Kuro-O

Elizabeth Megan Mclaughlin

Frederic A Fellouse

The invention describes methods and reagents useful for sequencing polypeptide molecules. The method comprises affixing a polypeptide to a substrate and contacting the polypeptide with a plurality of probes. Each probe selectively binds to an N-terminal amino acid or an N-terminal amino acid derivative. Probes bound to the polypeptide molecule are then identified before cleaving the N-terminal amino acid or N-terminal amino acid derivative of the polypeptide. Also provided are methods for the sequencing a plurality of polypeptide molecules in a sample and probes specific for N-terminal amino acids or N-terminal amino acid derivatives.

Protein sequencing method and reagents

There is provided herein a method for identifying and/or recovering at least one genetically encoded affinity reagent specific for a target molecule by screening using molecular display in conjunction with the sequencing of positive and negative selection pools from the screen.

Molecular display system

The invention provides novel synthetic antibodies directed against VEGF and uses thereof.

Synthetic antibodies against VEGF and their uses

This disclosure is directed to novel CD133-binding agents. The disclosure is also directed to uses of novel CD133-binding agents for detecting CD133-expressing cells and/or quantitating levels of cellular CD133 expression, for targeting CD133-expressing cells, for decreasing levels of CD133 in CD133-expressing cells and for treating or preventing cancer.

CD133-binding agents and uses thereof

Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.

Synthetic antibodies to BAX and uses thereof

An antibody and/or binding fragment thereof, wherein the antibody and/or binding fragment thereof comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining region (CDR) CDR-L3 and the heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3, with the amino acid sequences of said CDRs comprising one or more of the sequences set forth below: CDR-L3; selected from any one of SEQ ID NOs: 123, 126-130, 142, 148 or 149; CDR-H1: SEQ ID NOs: 121 or 124; CDR-H2; SEQ ID NOs: 122 or 125; and/or CDR-H3: selected from any one of SEQ ID NOs: 196-226.

Antibodies that specifically bind alpha klotho

An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.

EGFR-binding agents and uses thereof

The present disclosure is directed to novel FZD5-binding agents and methods and uses thereof for treating a disease or disorder associated with aberrant expression or activity of Frizzled protein.

Frizzled5 protein-binding agents

The present invention addresses a need for antibodies useful for filovirus infections.

Filovirus antibody

53BP1 inhibitors, compositions comprising the inhibitors and methods of using same are provided. The inhibitors can be used in combination with gene editing systems.

Ubiquitin variants and uses therof as 53BP1 inhibitors

An antibody and/or binding fragment thereof, wherein the antibody and/or binding fragment thereof specifically binds to an epitope of a &#x3b1;Klotho polypeptide, optionally a folded &#x3b1;Klotho or optionally with a dissociation constant (K) of about 2 nM or less, as measured by competitive ELISA assay, methods of making and using to diagnose kidney diseases.

Nucleic acids encoding antibodies with high affinity for Alpha-Klotho

This invention provides monoclonal antibodies that recognize one or more Frizzled receptors. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.

Antibodies against Frizzled receptor

Antibodies which specifically bind &#x3b1;Klotho polypeptide

Growing community of inventors

Toronto, Canada

Sachdev Singh Sidhu